Enan­ta's mid-stage win in pe­di­atric RSV; Caris­ma to lay off 34% of staff

Plus, news about In­novent Bi­o­log­ics, Rel­ma­da Ther­a­peu­tics, Zevra Ther­a­peu­tics, In­cyte and Bion­i­cal Emas:

Enan­ta’s Ph2 win in RSV: The com­pa­ny’s oral N-pro­tein in­hibitor

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER